Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
| + | *[[Media:2019_02-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|February 18, 2019]] | ||
*[[Media:2019_01-15_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 15, 2019]] | *[[Media:2019_01-15_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|January 15, 2019]] | ||
*[[Media:2018_11-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 20, 2018]] | *[[Media:2018_11-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|November 20, 2018]] | ||
| − | |||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 16:42, 26 March 2019
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- Secretary: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive